45,384 Shares in Progyny, Inc. (NASDAQ:PGNY) Bought by Entropy Technologies LP

Entropy Technologies LP bought a new position in Progyny, Inc. (NASDAQ:PGNY) in the 3rd quarter, Holdings Channel.com reports. The firm bought 45,384 shares of the company’s stock, valued at approximately $761,000.

Several other hedge funds also recently made changes to their positions in PGNY. Allspring Global Investments Holdings LLC lifted its stake in shares of Progyny by 9.5% in the first quarter. Allspring Global Investments Holdings LLC now owns 6,260 shares of the company’s stock valued at $239,000 after purchasing an additional 543 shares during the period. Janney Montgomery Scott LLC purchased a new position in Progyny during the 1st quarter valued at about $213,000. Swiss National Bank increased its holdings in Progyny by 0.6% during the 1st quarter. Swiss National Bank now owns 170,200 shares of the company’s stock valued at $6,493,000 after acquiring an additional 1,000 shares in the last quarter. Russell Investments Group Ltd. increased its holdings in Progyny by 15.0% during the 1st quarter. Russell Investments Group Ltd. now owns 135,904 shares of the company’s stock valued at $5,185,000 after acquiring an additional 17,701 shares in the last quarter. Finally, ProShare Advisors LLC increased its holdings in Progyny by 4.6% during the 1st quarter. ProShare Advisors LLC now owns 18,346 shares of the company’s stock valued at $700,000 after acquiring an additional 804 shares in the last quarter. Institutional investors and hedge funds own 94.93% of the company’s stock.

Analysts Set New Price Targets

PGNY has been the subject of several recent research reports. BTIG Research downgraded shares of Progyny from a “buy” rating to a “neutral” rating in a report on Wednesday, August 7th. Jefferies Financial Group dropped their target price on shares of Progyny from $31.00 to $24.00 and set a “buy” rating for the company in a report on Thursday, September 19th. Bank of America lowered their price target on shares of Progyny from $22.00 to $21.00 and set a “buy” rating for the company in a report on Wednesday. JPMorgan Chase & Co. lowered their price target on shares of Progyny from $31.00 to $22.00 and set an “overweight” rating for the company in a report on Thursday, September 19th. Finally, Leerink Partnrs downgraded shares of Progyny from a “strong-buy” rating to a “hold” rating in a report on Wednesday, August 7th. Eight equities research analysts have rated the stock with a hold rating and five have given a buy rating to the stock. According to MarketBeat, Progyny presently has a consensus rating of “Hold” and a consensus target price of $25.42.

Progyny Stock Performance

Progyny stock opened at $13.98 on Friday. Progyny, Inc. has a 1 year low of $13.77 and a 1 year high of $42.08. The firm has a 50 day moving average price of $17.49 and a 200 day moving average price of $23.49. The company has a market cap of $1.26 billion, a price-to-earnings ratio of 24.10, a PEG ratio of 1.62 and a beta of 1.44.

Progyny (NASDAQ:PGNY) last released its earnings results on Tuesday, November 12th. The company reported $0.11 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.37 by ($0.26). The company had revenue of $286.63 million during the quarter, compared to analysts’ expectations of $296.85 million. Progyny had a net margin of 5.03% and a return on equity of 10.87%. Progyny’s revenue for the quarter was up 2.0% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.16 earnings per share. Sell-side analysts predict that Progyny, Inc. will post 0.64 EPS for the current year.

About Progyny

Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.